Key result
Specific expression of human FSP27 in type 2 adipocytes in male mice reduced serum glycerol and nonesterified fatty acids after acute GH treatment and improved acute glucose intolerance.
Why the study?
To assess the physiological role of GH-mediated lipolysis mediated by type 2 white adipocytes, an adipocyte subpopulation with increased GH-induced signaling and lipolysis.
Answers are grounded in this paper and cite their sources.
GH-mediated FSP27 reduction may worsen insulin resistance; leaves open the role of adipocyte subpopulations in this pathway.
In adipose tissue, growth hormone (GH) stimulates lipolysis, leading to an increase in plasma free fatty acid levels and a reduction in insulin sensitivity. In our previous studies, we have found that GH increases lipolysis by reducing peroxisome proliferator-activated receptor γ (PPARγ) transcription activity, leading to a reduction of tat-specific protein 27 (FSP27, also known as CIDEC) expression. In previous studies, our laboratory uncovered 3 developmentally distinct subpopulations of white adipocytes. In this manuscript, we show that one of the subpopulations, termed type 2 adipocytes, has increased GH-induced signaling and lipolysis compared to other adipocyte subtypes. To assess the physiological role of GH-mediated lipolysis mediated by this adipocyte subpopulation, we specifically expressed human FSP27 (hFSP27) transgene in type 2 adipocytes (type2Ad-hFSP27tg mice). Systemically, male type2Ad-hFSP27tg mice displayed reduced serum glycerol release and nonesterified fatty acids levels after acute GH treatment, and improvement in acute, but not chronic, GH-induced glucose intolerance. Furthermore, we demonstrate that type2Ad-hFSP27tg mice displayed improved hepatic insulin signaling. Taken together, these results indicate that this adipocyte subpopulation is a critical regulator of the GH-mediated lipolytic and metabolic response. Thus, further investigation of adipocyte subpopulations may provide novel treatment strategies to regulate GH-induced glucose intolerance in patients with growth and metabolic disorders.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2023) studied Growth hormone-induced lipolysis and glucose intolerance. Expression of human FSP27 (hFSP27) transgene in type 2 adipocytes was evaluated on Serum glycerol release, nonesterified fatty acids levels, and glucose intolerance after acute GH treatment. Specific expression of human FSP27 in type 2 adipocytes in male mice reduced serum glycerol and nonesterified fatty acids after acute GH treatment and improved acute glucose intolerance.
Synapse has enriched 10 related papers. Consider them for comparative context: